In vitro studies suggest inhibiting NT5C2 could help treat
chemotherapy-resistant ALL. In the first study, whole-exome sequencing of 103
relapsed T cell and 35 B cell ALL samples identified 21 with mutations in NT5C2
that increased nucleotidase activity and were absent at diagnosis. In the
second study, gain-of-function mutations in NT5C2 were identified in 2
of 10 pediatric patients with B cell ALL at relapse that were absent at
diagnosis and in 5 of 61 additional relapsed samples in a follow-up study.
Next steps include developing diagnostic assays to identify the mutations and
developing NT5C2 inhibitors.

SciBX6(8);
doi:10.1038/scibx.2013.185
Published online Feb. 28, 2013

Patent application filed
covering findings in first study; available for licensing for diagnostic and
therapeutic applications

Access this BioCentury Innovations article Distillery article for your individual use via a permanent link that allows you to read or print the article: $18.
The article link will be posted on the purchase transaction web page, and also emailed to you with your purchase confirmation.

Purchase This Article for Limited One-Time Distribution and Posting to Your Website :

Receive a formatted PDF reprint of this article with rights for limited one-time redistribution and posting to your website: $750. Please allow 24-48 hours for delivery.

Purchase Options

Purchase this article for individual use $18 USDPurchase this article for limited one-time distribution and website posting $750 USD